Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AlphaMedix · 1 trial · 1 indication
The morphological imaging (CT/MRI) will be done before therapy and selected time points before therapy cycle to determine changes in the size of target lesions.
To assess the safety and tolerability of 212Pb-DOTAMTATE
| Arm | Type | Description |
|---|---|---|
| Pb212-DOTAMTATE | EXPERIMENTAL | investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors in PRRT naive patients (Cohort 1) and previous PRRT patients (Cohort 2) |
| Name | Type | Description |
|---|---|---|
| AlphaMedix | DRUG | 212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors |
Inclusion Criteria: * Male or female ≥18 years old with unresectable or metastatic histologically confirmed NET * Subjects must have received and progressed following somatostatin analog administration * For PRRT naive subjects, documented progression of disease following previous therapy within 12...
AlphaMedix is an investigational small molecule being studied for the treatment of Neuroendocrine Tumors. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in patients with Neuroendocrine Tumors, including those who have not received prior peptide receptor radionuclide therapy (PRRT) and those who have previously undergone PRRT.
AlphaMedix is a targeted alpha-emitter therapy, meaning it delivers alpha radiation to cancer cells. While the specific molecular target is not disclosed, the therapy is designed to treat Neuroendocrine Tumors by exploiting their biological characteristics. It is being studied in a Phase 2 trial to assess its safety and efficacy in this patient population.
AlphaMedix is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical research on AlphaMedix as an investigational therapy for Neuroendocrine Tumors, with the drug currently in Phase 2 development.
AlphaMedix is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is actively recruiting participants, though enrollment is complete, and the study is no longer recruiting new patients.
AlphaMedix is being evaluated in a single Phase 2 clinical trial registered as NCT05153772, titled 'Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients.' The trial is active but not recruiting, with an enrollment of 69 participants in the United States. It is an open-label, uncontrolled study.
AlphaMedix is not known to have alternative names. It is a distinct investigational small molecule developed by Sanofi for the treatment of Neuroendocrine Tumors. No other names or aliases for this drug have been disclosed in the available clinical trial information.